Profile
Portal Innovations is a venture capital firm based in Chicago, Illinois, founded in 2020. The firm specializes in supporting life sciences, medtech, and bioinformatics startups by providing seed capital, lab space, and management expertise. Portal Innovations operates with a team of 30 professionals and has a presence in multiple locations, including Chicago, Providence, and New Brunswick.
The firm focuses on investing in early-stage companies, particularly in the life sciences and healthcare sectors. It typically supports Series A and seed-stage startups, primarily in the United States, with some investments in Australia. Portal Innovations manages the Velocity Fund, which has an AUM of $100 million, launched in 2025.
Notable portfolio companies include Moonlight Therapeutics - clinical trials, Syntax Bio - drug discovery, CrossBridge Bio - acquired by Eli Lilly, Syntis Bio - drug discovery, and March Biosciences - drug discovery. These investments highlight Portal Innovations' commitment to advancing scientific breakthroughs in the biotech and healthcare industries.
Industry
Portal Innovations Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Velocity Fund
|
Venture Capital (VC)
|
Healthcare Services
MedTech
Technology
HealthTech
|
Pre-seed
Seed
|
North America
|
$5-10 m
|
$100 M
|
August 2025
|
|
Woodbine Labs, Powered by Portal
|
Venture Capital (VC)
|
Biotechnology
Life Sciences
|
Seed
Series A
Series B
|
North America
|
$1-5 m
|
—
|
March 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.